MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 1, 2004; DOI: 10.1124/mol.104.006700


0026-895X/05/6701-231-240$20.00
Mol Pharmacol 67:231-240, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.006700v1
67/1/231    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, C.
Right arrow Articles by Lovenberg, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, C.
Right arrow Articles by Lovenberg, T. W.

Relaxin-3/Insulin-Like Peptide 5 Chimeric Peptide, a Selective Ligand for G Protein-Coupled Receptor (GPCR)135 and GPCR142 over Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 7

Changlu Liu, Jingcai Chen, Chester Kuei, Steven Sutton, Diane Nepomuceno, Pascal Bonaventure, and Timothy W. Lovenberg

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., San Diego, California

Relaxin-3, the most recently identified member of relaxin/insulin family, is an agonist for leucine-rich repeat-containing G protein-coupled receptor (LGR)7, GPCR135, and GPCR142. LGR7 can be pharmacologically differentiated from GPCR135 and GPCR142 by its high affinity for relaxin. Selective ligands that specifically activate GPCR135 or GPCR142 are highly desirable for studying their functional roles. We have created chimeric peptides that consist of the B-chain of human relaxin-3 in combination with various A-chains from other members of the relaxin/insulin family. Pharmacological characterization of these chimeric peptides indicates the A-chain from relaxin-1, relaxin-2, insulin-like peptide (INSL)3, and INSL6 does not change the pharmacological properties of relaxin-3 significantly. In contrast, substitution of the relaxin-3 A-chain with the A-chain from INSL5 results in a chimeric peptide that selectively activates GPCR135 and GPCR142 over LGR7. This study demonstrates that the A-chains among some of the insulin/relaxin family members are pharmacologically exchangeable. The relaxin-3/INSL5 chimeric peptide is a potential tool to study in vivo function of GPCR135. In addition, because of the substitution of a very hydrophobic peptide (the A-chain of relaxin-3) with a very hydrophilic peptide (the A-chain from INSL5), the radiolabeled 125I-relaxin-3/INSL5 chimera is a suitable ligand (high-affinity, low-nonspecific binding) for receptor autoradiographic studies on tissue sections.


Received for publication August 30, 2004.

Accepted for publication September 30, 2004.

Address correspondence to: Dr. Changlu Liu, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., San Diego, CA 92121. E-mail: cliu9{at}prdus.jnj.com




This article has been cited by other articles:


Home page
Learn. Mem.Home page
S. Ma, F. E. Olucha-Bordonau, M. A. Hossain, F. Lin, C. Kuei, C. Liu, J. D. Wade, S. W. Sutton, A. Nunez, and A. L. Gundlach
Modulation of hippocampal theta oscillations and spatial memory by relaxin-3 neurons of the nucleus incertus
Learn. Mem., October 30, 2009; 16(11): 730 - 742.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Liu, J. Wu, J. Zhu, C. Kuei, J. Yu, J. Shelton, S. W. Sutton, X. Li, S. J. Yun, T. Mirzadegan, et al.
Lactate Inhibits Lipolysis in Fat Cells through Activation of an Orphan G-protein-coupled Receptor, GPR81
J. Biol. Chem., January 30, 2009; 284(5): 2811 - 2822.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. M. Haugaard-Jonsson, M. A. Hossain, N. L. Daly, R. A. D. Bathgate, J. D. Wade, D. J. Craik, and K. J. Rosengren
Structure of the R3/I5 Chimeric Relaxin Peptide, a Selective GPCR135 and GPCR142 Agonist
J. Biol. Chem., August 29, 2008; 283(35): 23811 - 23818.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. Hossain, K. J. Rosengren, L. M. Haugaard-Jonsson, S. Zhang, S. Layfield, T. Ferraro, N. L. Daly, G. W. Tregear, J. D. Wade, and R. A. D. Bathgate
The A-chain of Human Relaxin Family Peptides Has Distinct Roles in the Binding and Activation of the Different Relaxin Family Peptide Receptors
J. Biol. Chem., June 20, 2008; 283(25): 17287 - 17297.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Kuei, S. Sutton, P. Bonaventure, C. Pudiak, J. Shelton, J. Zhu, D. Nepomuceno, J. Wu, J. Chen, F. Kamme, et al.
R3(B{Delta}23 27)R/I5 Chimeric Peptide, a Selective Antagonist for GPCR135 and GPCR142 over Relaxin Receptor LGR7: IN VITRO AND IN VIVO CHARACTERIZATION
J. Biol. Chem., August 31, 2007; 282(35): 25425 - 25435.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. M. McGowan, S. A. Stanley, N. E. White, A. Spangeus, M. Patterson, E. L. Thompson, K. L. Smith, J. Donovan, J. V. Gardiner, M. A. Ghatei, et al.
Hypothalamic mapping of orexigenic action and Fos-like immunoreactivity following relaxin-3 administration in male Wistar rats
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E913 - E919.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
J. Novak, L. J. Parry, J. E. Matthews, L. J. Kerchner, K. Indovina, K. Hanley-Yanez, K. D. Doty, D. O. Debrah, S. G. Shroff, and K. P. Conrad
Evidence for local relaxin ligand-receptor expression and function in arteries
FASEB J, November 1, 2006; 20(13): 2352 - 2362.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics